专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130131319A1 ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE 审中-公开
标题翻译：具有改良亲和力的抗体促进抗原清除
公开(公告)号：US20130131319A1
公开(公告)日：2013-05-23
申请号：US13637415
申请日：2011-03-30
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
IPC分类号： C07K16/42
CPC分类号： C07K16/283 , A61K2039/505 , A61K2039/545 , C07K14/70535 , C07K16/18 , C07K16/248 , C07K16/28 , C07K16/2866 , C07K16/4241 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above. The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.
摘要翻译：本发明的目的是提供促进抗原结合分子介导的抗原向细胞摄取的方法，促进血浆中抗原浓度降低的方法，增加单一抗原结合分子所能抗原数目的方法结合，用于改善抗原结合分子的药代动力学的方法，改进用于促进抗原摄入细胞的抗原结合分子，能够促进血浆中抗原浓度降低的抗原结合分子，能够重复结合抗原的抗原结合分子，具有改善的药代动力学的抗原结合分子，包含这种抗原结合分子的药物组合物，以及用于制备上述那些的方法。本发明人发现，通过在血浆pH下具有人FcRn结合活性的抗体和在早期内体体内的pH低于等离子体pH下抗原结合活性较低的抗体促进了对细胞的吸收; 这样的抗体可以增加单个抗体分子可以结合的抗原的数量; 可以通过施用这样的抗体来促进血浆中抗原的降低; 可以通过使用这样的抗体来改善抗体药代动力学。

2. 发明申请

US20110111406A1 ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY 审中-公开
标题翻译：抗原结合分子能够绑定到两个或更多的抗原分子重复
公开(公告)号：US20110111406A1
公开(公告)日：2011-05-12
申请号：US12936587
申请日：2009-04-10
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
IPC分类号： C12Q1/68 , C07K16/00 , C07K16/44 , C12N5/071 , G01N33/53 , C12P21/02
CPC分类号： C12N15/1037 , A61K39/12 , A61K39/145 , A61K2039/505 , A61K2039/544 , A61K2039/545 , A61K2039/552 , C07K16/244 , C07K16/248 , C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2760/16111 , C12N2760/16134 , C12N2770/20071 , G01N33/6854 , G01N2500/00
摘要： The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
摘要翻译：本发明人发现，与血浆pH值相比，在早期内体体内具有较弱抗原结合活性的抗体能够用单一抗体分子与多个抗原分子结合，血浆半衰期长改善其与抗原结合的时间持续时间。

3. 发明申请

US20130011866A1 ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY 审中-公开
公开(公告)号：US20130011866A1
公开(公告)日：2013-01-10
申请号：US13595139
申请日：2012-08-27
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
IPC分类号： G01N33/53
CPC分类号： C12N15/1037 , A61K39/12 , A61K39/145 , A61K2039/505 , A61K2039/544 , A61K2039/545 , A61K2039/552 , C07K16/244 , C07K16/248 , C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2760/16111 , C12N2760/16134 , C12N2770/20071 , G01N33/6854 , G01N2500/00
摘要： The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

4. 发明授权

US08623360B2 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly 有权
公开(公告)号：US08623360B2
公开(公告)日：2014-01-07
申请号：US13595139
申请日：2012-08-27
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00
摘要： The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

5. 发明授权

US08562991B2 Antibody molecules that bind to IL-6 receptor 有权
标题翻译：结合IL-6受体的抗体分子
公开(公告)号：US08562991B2
公开(公告)日：2013-10-22
申请号：US12680087
申请日：2009-09-25
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译：本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物，以增强抗原 - 中和能力增强，药代动力学改善，治疗效果较差，免疫原性，安全性和物理化学性质（稳定性和均一性）均有改善。本发明还提供了制备这些药物组合物的方法。通过适当地组合CDR结构域，可变区和恒定区中的氨基酸序列改变，本发明人成功地生产出优于TOCILIZUMAB的第二代分子。

6. 发明申请

US20120253016A1 ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR 审中-公开
标题翻译：与IL-6受体结合的抗体分子
公开(公告)号：US20120253016A1
公开(公告)日：2012-10-04
申请号：US13524528
申请日：2012-06-15
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
IPC分类号： C07K16/00 , C12N15/63 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译：本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物，以增强抗原 - 中和能力增强，药代动力学改善，治疗效果较差，免疫原性，安全性和物理化学性质（稳定性和均一性）均有改善。本发明还提供了制备这些药物组合物的方法。通过适当地组合CDR结构域，可变区和恒定区中的氨基酸序列改变，本发明人成功地生产出优于TOCILIZUMAB的第二代分子。

7. 发明申请

US20140234340A1 ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO PLURALITY OF ANTIGEN MOLECULES REPEATEDLY 审中-公开
标题翻译：抗原分子分子与抗原分子重复结合的抗原结合分子
公开(公告)号：US20140234340A1
公开(公告)日：2014-08-21
申请号：US13990158
申请日：2011-11-30
申请人： Tomoyuki Igawa , Shinya Ishii , Miho Funaki , Naoka Hironiwa , Atsuhiko Maeda , Junichi Nezu , Yoshinao Ruike , Takeshi Baba , Shun Shimizu
发明人： Tomoyuki Igawa , Shinya Ishii , Miho Funaki , Naoka Hironiwa , Atsuhiko Maeda , Junichi Nezu , Yoshinao Ruike , Takeshi Baba , Shun Shimizu
IPC分类号： C07K16/18
摘要： An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.
摘要翻译：本发明的目的是提供通过抗原结合分子促进抗原摄入细胞的方法，增加一个抗原结合分子的抗原结合次数的方法，用于促进血浆中抗原浓度降低的方法施用抗原结合分子，以及用于改善抗原结合分子的血浆保留的方法以及允许增强抗原摄入细胞的抗原结合分子，具有增加的抗原结合次数的抗原结合分子，抗原当施用时可促进血浆中抗原浓度的降低的结合分子，具有改善的血浆滞留的抗原结合分子，包含上述抗原结合分子的药物组合物及其制备方法。本发明人发现，通过使用显示钙依赖性抗原 - 抗体反应的抗原结合分子，可以实现上述目的。

8. 发明申请

US20110098450A1 Antibody Molecules 有权
标题翻译：抗体分子
公开(公告)号：US20110098450A1
公开(公告)日：2011-04-28
申请号：US12680087
申请日：2009-09-25
申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
IPC分类号： C07K16/28 , C07H21/00 , C12N15/63 , C12P21/02 , C12N5/10
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译：本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物，以增强抗原 - 中和能力增强，药代动力学改善，治疗效果较差，免疫原性，安全性和物理化学性质（稳定性和均一性）均有改善。本发明还提供了制备这些药物组合物的方法。通过适当地组合CDR结构域，可变区和恒定区中的氨基酸序列改变，本发明人成功地生产出优于TOCILIZUMAB的第二代分子。

9. 发明授权

US10435458B2 Antibody constant region variants with reduced Fcgammar binding 有权
公开(公告)号：US10435458B2
公开(公告)日：2019-10-08
申请号：US13582073
申请日：2011-03-04
申请人： Taichi Kuramochi , Tomoyuki Igawa , Atsuhiko Maeda , Futa Mimoto
发明人： Taichi Kuramochi , Tomoyuki Igawa , Atsuhiko Maeda , Futa Mimoto
IPC分类号： C07K16/30 , C07K16/28 , C07K16/18 , C07K19/00 , C07K16/00
摘要： The present inventors carried out dedicated research to generate antibody constant regions with reduced Fcγ receptor-binding activity by altering amino acid sequences in the antibody constant region. As a result, the present inventors successfully identified novel constant region sequences with reduced Fcγ receptor-binding activity compared to conventional antibody constant regions.

10. 发明授权

US09228017B2 Antibody constant region variant 有权
标题翻译：抗体恒定区变体
公开(公告)号：US09228017B2
公开(公告)日：2016-01-05
申请号：US13257112
申请日：2010-03-19
申请人： Tomoyuki Igawa , Atsuhiko Maeda , Hirotake Shiraiwa
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Hirotake Shiraiwa
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K2317/52 , C07K2317/522 , C07K2317/526 , C07K2317/53 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
摘要翻译：通过改变氨基酸序列，本发明人成功地提供了可赋予具有良好性质的抗体的恒定区域，特别是作为药物。当应用于抗体生产时，由本发明提供的恒定区的变体将显着降低异质性。也就是说，通过将本发明提供的改变引入抗体重链恒定区，可以将抗体的均一性保持在高水平。更具体地，可以防止由抗体分子的重链中的-SS-键连接差引起的同质性的降低。此外，在本发明的优选实施方案中，可以改善抗体的药代动力学，并且可以改善由抗体恒定区中的C末端缺失引起的同质性降低。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式